Key result
Stimulating myocardial pyruvate dehydrogenase activity with dichloroacetate failed to alleviate cardiac hypertrophy or improve cardiac function in a mouse model of Barth syndrome.
Why the study?
Because stimulating myocardial glucose oxidation alleviates diabetic cardiomyopathy and heart failure, the authors tested whether stimulating pyruvate dehydrogenase activity could alleviate cardiac hypertrophy in Barth syndrome.
Does dichloroacetate improve cardiac hypertrophy and function in a mouse model of Barth syndrome?
Does dichloroacetate improve cardiac hypertrophy and function in a mouse model of Barth syndrome?
Stimulating myocardial pyruvate dehydrogenase activity with dichloroacetate does not alleviate cardiac hypertrophy or dysfunction in a mouse model of Barth syndrome.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for PDH-targeted metabolic therapy in BTHS; leaves open translation from murine models to patients.
Barth syndrome (BTHS) is a rare genetic disorder due to mutations in the TAFAZZIN gene, leading to impaired maturation of cardiolipin and thereby adversely affecting mitochondrial function and energy metabolism, often resulting in cardiomyopathy. In a murine model of BTHS involving short-hairpin RNA mediated knockdown of Tafazzin (TazKD mice), myocardial glucose oxidation rates were markedly reduced, likely secondary to an impairment in the activity of pyruvate dehydrogenase (PDH), the rate-limiting enzyme of glucose oxidation. Furthermore, TazKD mice exhibited cardiac hypertrophy with minimal cardiac dysfunction. Because the stimulation of myocardial glucose oxidation has been shown to alleviate diabetic cardiomyopathy and heart failure, we hypothesized that stimulating PDH activity would alleviate the cardiac hypertrophy present in TazKD mice. In order to address our hypothesis, 6-week-old male TazKD mice and their wild-type (WT) littermates were treated with dichloroacetate (DCA; 70 mM in the drinking water), which stimulates PDH activity via inhibiting PDH kinase to prevent inhibitory phosphorylation of PDH. We utilized ultrasound echocardiography to assess cardiac function and left ventricular wall structure in all mice prior to and following 6-weeks of treatment. Consistent with systemic activation of PDH and glucose oxidation, DCA treatment improved glycemia in both TazKD mice and their WT littermates, and decreased PDH phosphorylation equivalently at all 3 of its inhibitory sites (serine 293/300/232). However, DCA treatment had no impact on left ventricular structure, or systolic and diastolic function in TazKD mice. Therefore, it is unlikely that stimulating glucose oxidation is a viable target to improve BTHS-related cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Greenwell et al. (2022) studied Barth syndrome cardiomyopathy (mouse model). Dichloroacetate (DCA) vs. Control (water) was evaluated on Left ventricular structure and function (e.g., cardiac hypertrophy, cardiac output, ejection fraction). Stimulating myocardial pyruvate dehydrogenase activity with dichloroacetate failed to alleviate cardiac hypertrophy or improve cardiac function in a mouse model of Barth syndrome.
Synapse has enriched 10 related papers. Consider them for comparative context: